A Case of Acute Kidney Injury Associated With Dabrafenib and Trametinib Treatment for Metastatic Melanoma

Abstract

Get full access to this article

View all access options for this article.

References

Long

Stroyakovskiy

Gogas

et al . Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371:1877-1888. doi:10.1056/NEJMoa1406037

Jansen

Janssens

Hoorens

et al . Granulomatous nephritis and dermatitis in a patient with BRAF V600E mutant metastatic melanoma treated with dabrafenib and trametinib. Melanoma Res. 2015;25:550-554. doi:10.1097/CMR.0000000000000186

Jhaveri

Sakhiya

Fishbane

Nephrotoxicity of the BRAF inhibitors vemurafenib and dabrafenib. JAMA Oncol. 2015;1:1133-1134. doi:10.1001/jamaoncol.2015.1713

Ouellet

Gibiansky

Leonowens

et al . Population pharmacokinetics of dabrafenib, a BRAF inhibitor: effect of dose, time, covariates, and relationship with its metabolites. J Clin Pharmacol. 2014;54:696-706. doi:10.1002/jcph.263

Naranjo

Busto

Sellers

et al . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-245. doi:org/10.1038/clpt.1981.154